| Literature DB >> 23942878 |
Teresa Gervasi1, Nikki Horn, Udo Wegmann, Giacomo Dugo, Arjan Narbad, Melinda J Mayer.
Abstract
Clostridium perfringens is a cause for increasing concern due to its responsibility for severe infections both in humans and animals, especially poultry. To find new control strategies to treat C. perfringens infection, we investigated the activity and delivery of a bacteriophage endolysin. We identified a new endolysin, designated CP25L, which shows similarity to an N-acetylmuramoyl-L-alanine amidase domain and is distinct from other C. perfringens endolysins whose activity has been demonstrated in vitro. The cp25l gene was cloned and expressed in Escherichia coli, and the gene product demonstrated lytic activity against all 25 C. perfringens strains tested. The probiotic strain Lactobacillus johnsonii FI9785 was engineered to deliver the endolysin to the gastrointestinal tract. The integration of the nisRK two-component regulatory system from the Lactococcus lactis nisin A biosynthesis operon into the chromosome of L. johnsonii allowed constitutive expression of the endolysin under the control of the nisA promoter (P nisA ), while the use of a signal peptide (SLPmod) led to successful secretion of the active endolysin to the surrounding media. The high specificity and activity of the endolysin suggest that it may be developed as an effective tool to enhance the control of C. perfringens by L. johnsonii in the gastrointestinal tract.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23942878 PMCID: PMC3936119 DOI: 10.1007/s00253-013-5128-y
Source DB: PubMed Journal: Appl Microbiol Biotechnol ISSN: 0175-7598 Impact factor: 4.813
Lytic activity of CP25L against sensitive strains
| Lytic activitya | |||
|---|---|---|---|
| Bacterial strains | CP25L | Lag (min) | Lysozyme |
|
| 79.5 ± 1.0 | 1 | – |
|
| 59.2 ± 0.9 | 6 | 21.8 ± 1.5 |
|
| 28.6 ± 0.4 | 6 | 10.6 ± 0.6 |
|
| 58.8 ± 4.4 | 4 | 8.5 ± 0.5 |
|
| 17.1 ± 2.5 | 10 | 5.6 ± 0.9 |
|
| 39.8 ± 3.1 | 10 | 22.5 ± 0.0 |
|
| 23.0 ± 0.2 | – | 16.7 ± 0.4 |
|
| 44.6 ± 0.7 | 2 | 30.2 ± 0.6 |
|
| 50.7 ± 1.7 | 4 | 25.4 ± 1.0 |
|
| 70.5 ± 1.7 | 8 | 15.6 ± 0.1 |
|
| 34.2 ± 0.4 | – | 17.5 ± 0.8 |
|
| 38.0 ± 0.7 | – | 16.7 ± 0.0 |
|
| 38.8 ± 0.3 | – | 22.0 ± 0.0 |
|
| 37.9 ± 0.6 | 8 | – |
|
| 39.4 ± 1.2 | 15 | 20.2 ± 2.7 |
|
| 49.4 ± 2.0 | – | 9.8 ± 0.3 |
|
| 46.4 ± 2.3 | 4 | 7.3 ± 0.0 |
|
| 39.4 ± 2.1 | 6 | – |
|
| 35.7 ± 0.0 | – | 24.3 ± 0.0 |
|
| 46.2 ± 1.8 | – | 15.7 ± 0.4 |
|
| 37.5 ± 5.9 | 4 | – |
|
| 35.4 ± 0.2 | 6 | – |
|
| 26.5 ± 9.7 | 22 | – |
|
| 37.8 ± 0.5 | – | – |
|
| 5.5 ± 0.2 | 6 | – |
|
| 17.3 ± 1.3 | 6 | 46.7 ± 1.5 |
|
| 5.5 ± 2.5 | 6 | – |
|
| 9.5 ± 0.3 | 18 | 33.2 ± 1.3 |
|
| 56.6 ± 0.5 | 4 | – |
|
| 13.5 ± 2.3 | 6 | 46.6 ± 1.0 |
a Percent drop in OD600 in 4 min linear lysis (mean ± standard deviation), dash no lysis/lag
bStrains kindly provided by Dr. M. Brett, (HPA, UK)
cStrains kindly provided by Prof. R La Ragione (AHVLA, UK)
Strains resistant to lysis by CP25L
| Bacterial strains |
|---|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fig. 1Alignment of the amino acid sequence of CP25L compared with putative N-acetylmuramoyl-l-alanine amidases from C. perfringens genomes identified by Blastp analysis. Coloring of letters indicates degree of amino acid conservation between sequences (black, 100 %, dark grey 80 %, light grey 60 %); lines above CP25L sequence indicate areas of homology with the PGRP and amidase_2 domains (black line) or the SH3_3 bacterial domain (grey)
Fig. 2Expression of CP25L in E. coli. a SDS-PAGE analysis of products from Ni-NTA column purification. Lanes 1, SeeBlue Plus2 marker, 2, cell lysate, 3, column flow through, 4–5 column washes, 6–8 successive 1 ml column eluates. Lanes contain 3.25 μl samples. b, c Lytic activity of Ni-NTA-purified protein on C. perfringens showing the effect of protein concentration (b) and lysis medium (c). b Closed square, 100 μg/ml; open square, 33 μg/ml; small closed square, 3 μg/ml; closed triangle, 0.3 μg/ml; and open triangle, 0.03 μg/ml of CP25L compared with buffer control (EB, closed circle). c Cells were resuspended in PBS (closed circle), BHI + C, (closed triangle), or CM (closed square) and incubated with 33 μg/ml CP25L (closed symbols) or EB (open symbols). Results are the mean of duplicate assays ± standard deviation
Fig. 3CP25L stability. Endolysin activity was measured in turbidity reduction assays using 33 μg/ml Ni-NTA-purified protein. Results represent the activity of samples stored at room temperature as a percentage of the activity of endolysin stored at 4 °C assayed at the same time; activity was calculated as the percent decrease in OD600 over 4 min of linear lysis using the mean of duplicate assays ± standard deviation
Fig. 4Viability assays under anaerobic conditions to examine the effect of 33 μg/ml Ni-NTA-purified CP25L (black bars) on the viability of C. perfringens in comparison with the buffer control (white bars). Endolysin was added to the media either at point of inoculation (0 h) (a), or during the early exponential phase (OD600 0.3, 3.5 h) (b)
Fig. 5Endolysin expression in L. johnsonii. Frozen cells of C. perfringens were incubated with 33 μg/ml crude protein extracts from L. johnsonii FI10744-L (filled square) or FI10744-V (filled triangle), or EB (open circle). Filled symbols were from cultures induced with nisin; open symbols had no exposure to nisin. Results are the mean of duplicate assays ± standard deviation
Fig. 6Endolysin delivery from L. johnsonii. a Plate assay showing lysis from crude protein extracts (1–4) and concentrated supernatants (5–7, 20× concentrated; 9–12, 166× concentrated) from L. johnsonii FI10744-L induced with nisin (1, 5, 9) or uninduced (3, 7, 11), L. johnsonii FI10744-V induced with nisin (2, 6, 10) or uninduced (4, 12); 8, EB control. b Lytic zones produced by growing colonies of FI10744-L (L) compared with control FI10744-V (V) on media incorporating autoclaved C. perfringens